If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Marcello Curvietto is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 2 Similar Profiles
Melanoma Medicine & Life Sciences
fotemustine Medicine & Life Sciences
Immunotherapy Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Electrochemotherapy Medicine & Life Sciences
Survival Medicine & Life Sciences
Clinical Trials Medicine & Life Sciences
Small Cell Lung Carcinoma Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2013 2019

  • 414 Citations
  • 6 h-Index
  • 11 Article
Biological Factors
Antineoplastic Agents
clinical trials
Clinical Trials
Costs and Cost Analysis

Nivolumab for the treatment of small cell lung cancer

Simeone, E., Grimaldi, A. M., Festino, L., Trojaniello, C., Vitale, M. G., Vanella, V., Curvietto, M. & Ascierto, P. A., Jan 1 2019, (Accepted/In press) In : Expert Review of Respiratory Medicine.

Research output: Contribution to journalArticle

Small Cell Lung Carcinoma
Drug Therapy
Immunotherapy
Clinical Trials
Therapeutics
9 Citations (Scopus)

Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma

Simeone, E., Grimaldi, A. M., Festino, L., Giannarelli, D., Vanella, V., Palla, M., Curvietto, M., Esposito, A., Palmieri, G., Mozzillo, N. & Ascierto, P. A., Mar 4 2017, In : OncoImmunology. 6, 3, e1283462.

Research output: Contribution to journalArticle

Melanoma
Immunotherapy
Therapeutics
Disease-Free Survival
pembrolizumab

Combined vemurafenib and fotemustine in patients with BRAFV600 melanoma progressing on vemurafenib

Queirolo, P., Spagnolo, F., Picasso, V., Spano, L., Tanda, E., Fontana, V., Giorello, L., Merlo, D. F., Simeone, E., Grimaldi, A. M., Curvietto, M., Del Vecchio, M., Bruzzi, P. & Ascierto, P. A., Jul 13 2016, In : Oncotarget.

Research output: Contribution to journalArticle

fotemustine
Melanoma
PLX4032
Therapeutics
Survival

Combined vemurafenib and fotemustine in patients with BRAFV600 melanoma progressing on vemurafenib.

Queirolo, P., Spagnolo, F., Picasso, V., Spano, L., Tanda, E., Fontana, V., Giorello, L., Merlo, D. F., Simeone, E., Grimaldi, A. M., Curvietto, M., Del Vecchio, M., Bruzzi, P. & Ascierto, P. A., Jul 1 2016, In : Oncotarget.

Research output: Contribution to journalArticle